Patient Factors Considered when Choosing Treatment Selection

Opinion
Video

Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr.Thawani asks Dr Garon:How do you approach choosing between the different ALK inhibitors available?
  • What factors guide your selection, and in which cases might you prefer alectinib, lorlatinib, or brigatinib?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content